Paclitaxel News and Research

RSS
Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.
Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Reducing the incidence of drug-induced interstitial lung disease in breast cancer patients

Researchers develop new nano drug that kills triple-negative breast cancer cells

Researchers develop new nano drug that kills triple-negative breast cancer cells

Cocktail of chemotherapy drugs may be safe, effective for patients with metastatic pancreatic cancer

Cocktail of chemotherapy drugs may be safe, effective for patients with metastatic pancreatic cancer

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Common chemotherapy drug may be less effective in overweight, obese breast cancer patients

Inflammatory changes in tumors can cause drug resistance in cancer blood vessels

Inflammatory changes in tumors can cause drug resistance in cancer blood vessels

Combination therapy improves survival rates for women with aggressive endometrial cancer

Combination therapy improves survival rates for women with aggressive endometrial cancer

International trial shows better option for treating people with inoperable anal cancer

International trial shows better option for treating people with inoperable anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Study finds carboplatin-paclitaxel as the optimal chemotherapy for anal cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Study compares cediranib plus olaparib and standard of care therapy for platinum-sensitive ovarian cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Addition of monoclonal antibody to trimodality therapy offers no benefit in HER2 over expressing esophageal cancer

Targeted drugs shrink breast cancer tumors in mice without toxic side effects

Targeted drugs shrink breast cancer tumors in mice without toxic side effects

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

SWOG scientists to deliver online presentations at ASCO20 Virtual Scientific Program

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Immunotherapy before surgery may help eradicate high-risk breast cancer

Immunotherapy before surgery may help eradicate high-risk breast cancer

Combinations of PAC and WFA are highly synergistic against proliferation of non-small cell lung cancer

Combinations of PAC and WFA are highly synergistic against proliferation of non-small cell lung cancer

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Scientists find gene signature for poor response to standard therapy in rare uterine cancer

Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumors

Targeting PI3Kβ alone and with combination therapy in PTEN-deficient tumors

Combination of anti-cancer nanodrugs with Intralipid enhances therapeutic efficacy

Combination of anti-cancer nanodrugs with Intralipid enhances therapeutic efficacy

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

Administering immunotherapy alongside chemoradiation for advanced NSCLC appears to be safe and tolerable

NUS researchers identify new protein to prevent chemotherapy-induced neuropathy

NUS researchers identify new protein to prevent chemotherapy-induced neuropathy